Xbrane develops biosimilars on originator products where we believe we can make a significant difference in terms of improved accessibility with lower pricing. Xbrane has a portfolio of four biosimilar candidates for a range of treatment areas, three of which are under active development. This includes several serious eye diseases, several different types of cancer and, among others, rheumatoid arthritis, psoriasis and Crohn’s disease.
Our portfolio of proposed biosimilars
Biosimilar candidate | Originial drug | Primary indication | Estimated annual peak year sales of original drug* | Patent expiry of original drug | Development phase |
---|---|---|---|---|---|
Ximluci® | Ranibizumab (Lucentis®) | Wet age-related macular degeneration, diabetes-related eye damage and retinal vein occlusion. | EUR 3 bn* | 2020 (USA) 2022 (Europe) | Launch phase |
BIIB801 | Certolizumab pegol (Cimzia®) | Rheumatoid arthritis, axial spondylitis, psoratic arthritis. | EUR 2 bn* | 2024 (USA) 2025 (Europe) | Preclinical phase |
Xdivane™ | Nivolumab (Opdivo®) | Skin cancer, lung cancer, renal cell cancer, head and neck cancer and bladder and urinary tract cancer. | EUR 13 bn* | 2026 - 2031 depending on country | Preclinical phase |
Xdarzane™ | Daratumumab (Darzalex®) | Multiple melanoma. | EUR 9 bn* | 2029 - 2031 depending on country | Preclinical phase |
1Source: *Evaluate Pharma; "Originator Peak Sales Estimate 2026"